ADPT · Insider Trading

Adaptive Biotechnologies Corporation Common Stock

Every open-market purchase and sale reported by ADPT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
19
code S
Reporting Insiders
12
current holders
ADPT — Recent Form 4 Transactions (latest 2026-11-06)
FiledInsiderRole TypeSharesValue
2026-11-06 Julie Rubinstein President and COO MIXED — −$521.74K
2026-11-03 Julie Rubinstein President and COO MIXED — −$496.19K
2026-10-29 Julie Rubinstein President and COO MIXED — −$565.39K
2026-10-26 Julie Rubinstein President and COO MIXED — −$464.75K
2026-10-21 Julie Rubinstein President and COO MIXED — −$446.38K
2026-10-16 Julie Rubinstein President and COO MIXED — −$464.65K
2026-10-13 Julie Rubinstein President and COO MIXED — −$487.16K
2026-10-08 Susan Bobulsky Chief Commercial Officer, MRD Sell −6,444 −$193.32K
2026-10-08 Julie Rubinstein President and COO MIXED — −$515.52K
2026-10-05 Julie Rubinstein President and COO MIXED — −$581.62K
2026-10-05 Francis Lo Chief People Officer MIXED — −$576.14K
2026-09-18 Francis Lo Chief People Officer MIXED −9,846 −$2.23M
2026-09-17 Susan Bobulsky Chief Commercial Officer, MRD Sell −1,195 −$32.27K
2026-09-02 Katey Einterz Owen Director G −12,539 —
2026-08-28 Katey Einterz Owen Director Sell −9,615 −$249.99K
2026-08-20 Robert Hershberg Director MIXED −15,664 −$653.41K
2026-08-19 Peter M Neupert Director MIXED −109,690 −$3.04M
2026-08-19 Chad M Robins CEO and Chairman MIXED — −$10.95M
2026-08-12 Susan Bobulsky Chief Commercial Officer, MRD Sell −3,000 −$75.00K
2026-08-03 Susan Bobulsky Chief Commercial Officer, MRD Sell −1,299 −$31.18K
2026-07-23 Harlan S Robins Chief Scientific Officer MIXED −207,600 −$8.91M
2026-07-20 Susan Bobulsky Chief Commercial Officer, MRD Sell −5,000 −$115.00K
2026-07-17 Francis Lo Chief People Officer MIXED — −$1.45M
2026-07-07 Harlan S Robins Chief Scientific Officer Sell −386,240 −$8.50M
2026-07-06 Susan Bobulsky Chief Commercial Officer, MRD Sell −487 −$10.71K
2026-07-06 Francis Lo Chief People Officer MIXED −20,221 −$1.50M
2026-06-29 Susan Bobulsky Chief Commercial Officer, MRD Sell −5,000 −$102.50K
2026-06-29 Michelle Renee Griffin Director MIXED — −$644.80K
2026-06-17 Harlan S Robins Chief Scientific Officer Sell −106,160 −$1.85M
2026-06-15 Susan Bobulsky Chief Commercial Officer, MRD Sell −5,000 −$95.00K
2026-06-08 Susan Bobulsky Chief Commercial Officer, MRD Sell −11,000 −$198.00K
2026-06-08 Francis Lo Chief People Officer MIXED −20,220 −$522.27K
2026-05-20 Kyle Piskel Chief Financial Officer Sell −3,115 −$40.62K
2026-04-29 Julie Rubinstein President and COO MIXED −4,330 −$146.48K
2026-04-24 Julie Rubinstein President and COO MIXED −13,014 −$424.78K
2026-04-21 Julie Rubinstein President and COO MIXED −13,014 −$490.74K
2026-04-16 Julie Rubinstein President and COO MIXED −13,014 −$452.61K
2026-04-13 Julie Rubinstein President and COO MIXED −13,014 −$429.15K
2026-04-10 Francis Lo Chief People Officer MIXED −20,220 −$330.69K
2026-04-10 Harlan S Robins Chief Scientific Officer Sell −10,000 −$148.50K
2026-04-08 Chad M Robins CEO and Chairman Sell −120,595 −$1.77M
2026-04-08 Julie Rubinstein President and COO MIXED −13,014 −$525.18K
2026-04-02 Julie Rubinstein President and COO MIXED −8,676 −$339.64K
2026-03-26 Julie Rubinstein President and COO MIXED −13,014 −$481.15K
2026-03-23 Julie Rubinstein President and COO MIXED −13,014 −$461.99K
2026-03-18 Julie Rubinstein President and COO MIXED −13,014 −$472.92K
2026-03-13 Susan Bobulsky Chief Commercial Officer, MRD Sell −41,338 −$544.42K
2026-03-13 Francis Lo Chief People Officer Sell −30,593 −$430.75K
2026-03-13 Michelle Renee Griffin Director Sell −15,394 −$214.13K
2026-03-13 Kyle Piskel Chief Financial Officer Sell −18,672 −$245.91K
ADPT — Current Insider Holders
InsiderRole Shares HeldValue
Chad M Robins CEO and Chairman 2,683,043 $81.19M
Harlan S Robins Chief Scientific Officer 1,312,058 $39.70M
Susan Bobulsky Chief Commercial Officer, MRD 389,350 $11.78M
Julie Rubinstein President and COO 377,802 $11.43M
Sharon Benzeno Chief Commercial Ofc Imm Med 272,751 $8.25M
Kyle Piskel Chief Financial Officer 256,725 $7.77M
Peter M Neupert Director 255,315 $7.73M
Francis Lo Chief People Officer 242,065 $7.32M
Robert Hershberg Director 77,347 $2.34M
Michael J Pellini Director 69,690 $2.11M
Katey Einterz Owen Director 66,100 $2.00M
Michelle Renee Griffin Director 15,625 $472.81K
ADPT Insider Trading FAQ
Who are the insiders at ADPT?
12 officers, directors and 10%+ beneficial owners currently report holdings in ADPT via SEC Form 4.
Are ADPT insiders buying or selling?
Across the 50 most recent Form 4 filings for ADPT, 0 were open-market purchases (code P) and 19 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is ADPT insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent ADPT filing is dated 2026-11-06.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the ADPT quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.